Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cells

Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego.

Dr. Pilon-Thomas of Moffitt said, "With only 8 patients we've been able to clearly observe statistically significant increases in beneficial T cell populations in peripheral blood. Ironically, the original aim of the trial to assess tumor-infiltrating lymphocytes was thwarted when biopsies of patient tumors collected just 7-14 days after PV-10 injection no longer contained viable tumor tissue. We are following up both the human data and continuing to design more experiments in mice to better explain the systemic immune effects elicited by PV-10 ablation.”

Dr. Craig Dees, PhD, CEO, of Provectus Provectus' spoke about the investigational drug PV-10. He said, "As more data become available on the ‘bystander effect' we've consistently observed in our therapeutic trials, we can better position PV-10 to help the most patients. We are grateful to the team conducting the work upon which the poster was based, and believe that their findings further establish the potential PV-10 has as a powerful tool in the physician's toolbox to fight cancer.”

For more information go to: http://1.usa.gov/1oHlPDe.